HTGC

Business Context and Reporting Period

Hercules Capital, Inc. (HTGC) is a specialty finance company and Business Development Company (BDC) focused on providing senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors. This Form 10-Q covers the quarterly period ended September 30, 2020.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income Decline: Net increase in net assets from operations for the nine months ended September 30, 2020, was $76.1 million, a significant decrease from $129.0 million in the same period in 2019. This was primarily driven by net realized losses of $41.4 million in 2020 compared to net realized gains of $13.6 million in 2019.
• Realized Losses: The company recorded gross realized losses of $57.6 million for the nine months ended September 30, 2020, largely due to write-offs of debt investments in Patron Technology and Motif BioSciences, Inc.
• Investment Income Growth: Despite the net income decline, total investment income increased to $211.9 million (nine months 2020) from $197.3 million (nine months 2019), driven by an increase in the weighted average principal outstanding of loans and accelerated income from early repayments.
• Portfolio Composition: The portfolio value increased to $2.42 billion from $2.31 billion at year-end 2019. The "Drug Discovery & Development" sector now represents 35.6% of the portfolio, up from 32.2%.
• Debt Issuance: The company issued $50.0 million of February 2025 Notes and $70.0 million of June 2025 Notes during the period, increasing total borrowings.

Guidance, Outlook, and Risks

• COVID-19 Impact: Management continues to monitor the pandemic's impact. While it negatively affected net assets from operations in the first nine months of 2020, total investment income and net investment income increased compared to prior periods. The long-term impact remains uncertain.
• Liquidity: As of September 30, 2020, the company had $465.1 million in available liquidity, including $27.6 million in cash and $437.5 million in available borrowing capacity under credit facilities (Wells and Union Bank).
• Asset Coverage: The asset coverage ratio was 197.0% (excluding SBA debentures) and 189.7% (including SBA debentures), well above the regulatory minimum of 150%.
• Distributions: The Board declared a quarterly distribution of $0.32 per share and a supplemental distribution of $0.02 per share for the quarter ended September 30, 2020.
• Risks: Key risks include the potential for further portfolio company defaults due to the economic downturn, the volatility of the stock price trading below NAV, and the uncertainty surrounding the valuation of Level 3 assets (private investments).

Investor Verification Checklist

• Write-off Details: Verify the specific circumstances and remaining exposure related to the write-offs of Patron Technology and Motif BioSciences, Inc., which drove the $41.4 million net realized loss.
• Portfolio Grading: Review the increase in "Grade 3" investments (34.1% of portfolio) compared to the prior year (23.7%) to assess credit quality deterioration.
• Unfunded Commitments: Confirm the company's ability to fund the $242.5 million in unfunded contractual commitments given current cash flows and borrowing capacity.
• NAV vs. Market Price: Monitor the spread between the NAV per share ($10.26) and the market price ($11.57 at period end) to assess capital raising capabilities.
• Interest Rate Sensitivity: Evaluate the impact of rising interest rates on the company's floating-rate debt portfolio (97.9% of loans) versus its fixed-rate borrowings.